Meeting
2020 ASCO Virtual Scientific Program
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
Authors
David R. Spigel
Sarah Cannon Research Institute, Nashville, TN
David R. Spigel , Luis G. Paz-Ares , Yuanbin Chen , Maria Jove , Oscar Juan-Vidal , Patricia Rich , Theresa M. Hayes , M Vanesa Gutierrez Calderon , Reyes Bernabe Caro , Alejandro Navarro , Afshin Dowlati , Bin Zhang , Yan Moore , Haofei Tiffany Wang , Jaba Kokhreidze , Natalya Nazarenko , Santiago Ponce Aix , Paul Bunn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03088813
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9069)
DOI
10.1200/JCO.2020.38.15_suppl.9069
Abstract #
9069
Poster Bd #
262
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
First Author: Luis G. Paz-Ares
Poster
2024 ASCO Breakthrough
Real-world outcomes with lurbinectedin in second-line and beyond for small cell lung cancer in Korea.
First Author: Joosung Gabriel Shim
Poster
2022 ASCO Annual Meeting
Study protocol of an open-label, single-arm, phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).
First Author: Linde Kehmann
Poster
2019 Gastrointestinal Cancers Symposium
Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.
First Author: Zev A. Wainberg